Associated Genetic Biomarkers
MAGEA6 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain MAGEA6 status as an inclusion criterion, 2 are phase 1 (1 open).
Trials with MAGEA6 status in the inclusion eligibility criteria most commonly target breast carcinoma and malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is MAGEA6 Expression .
Kite-718, cyclophosphamide, fludarabine, and rvv-740cta vaccine are the most frequent therapies in trials with MAGEA6 as an inclusion criteria .
Significance of MAGEA6 in Diseases
Breast Carcinoma +
MAGEA6 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGEA6 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Malignant Solid Tumor +
MAGEA6 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAGEA6 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.